Protalix Biotherapeutics Inc (NYSE MKT:PLX) — Market Cap & Net Worth
Market Cap & Net Worth: Protalix Biotherapeutics Inc (PLX)
Protalix Biotherapeutics Inc (NYSE MKT:PLX) has a market capitalization of $156.31 Million ($156.31 Million) as of May 26, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #17622 globally and #4032 in its home market, demonstrating a 5.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Protalix Biotherapeutics Inc's stock price $2.10 by its total outstanding shares 80571642 (80.57 Million). Analyse Protalix Biotherapeutics Inc operating cash flow efficiency to see how efficiently the company converts income to cash.
Protalix Biotherapeutics Inc Market Cap History: 2015 to 2026
Protalix Biotherapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $821.83 Million to $169.20 Million (-13.53% CAGR).
Protalix Biotherapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Protalix Biotherapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.75x
Protalix Biotherapeutics Inc's market cap is 2.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $358.54 Million | $9.20 Million | -$29.36 Million | 38.98x | N/A |
| 2017 | $532.74 Million | $21.08 Million | -$83.44 Million | 25.27x | N/A |
| 2018 | $250.58 Million | $34.24 Million | -$26.46 Million | 7.32x | N/A |
| 2019 | $264.27 Million | $54.69 Million | -$18.28 Million | 4.83x | N/A |
| 2020 | $292.48 Million | $62.90 Million | -$6.52 Million | 4.65x | N/A |
| 2021 | $67.01 Million | $38.35 Million | -$27.58 Million | 1.75x | N/A |
| 2022 | $110.38 Million | $47.64 Million | -$14.93 Million | 2.32x | N/A |
| 2023 | $143.42 Million | $65.49 Million | $8.31 Million | 2.19x | 17.25x |
| 2024 | $151.47 Million | $53.40 Million | $2.93 Million | 2.84x | 51.66x |
| 2025 | $145.03 Million | $52.74 Million | -$6.60 Million | 2.75x | N/A |
Competitor Companies of PLX by Market Capitalization
Companies near Protalix Biotherapeutics Inc in the global market cap rankings as of May 26, 2026.
Key companies related to Protalix Biotherapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.28 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #417 globally with a market cap of $65.82 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #583 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #605 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.28 Billion | $434.52 |
| #417 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $65.82 Billion | $638.88 |
| #583 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #605 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Protalix Biotherapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Protalix Biotherapeutics Inc's market cap moved from $821.83 Million to $ 169.20 Million, with a yearly change of -13.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $169.20 Million | +16.67% |
| 2025 | $145.03 Million | -4.26% |
| 2024 | $151.47 Million | +5.62% |
| 2023 | $143.42 Million | +29.93% |
| 2022 | $110.38 Million | +64.72% |
| 2021 | $67.01 Million | -77.09% |
| 2020 | $292.48 Million | +10.67% |
| 2019 | $264.27 Million | +5.47% |
| 2018 | $250.58 Million | -52.96% |
| 2017 | $532.74 Million | +48.58% |
| 2016 | $358.54 Million | -56.37% |
| 2015 | $821.83 Million | -- |
End of Day Market Cap According to Different Sources
On May 26th, 2026 the market cap of Protalix Biotherapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $156.31 Million USD |
| MoneyControl | $156.31 Million USD |
| MarketWatch | $156.31 Million USD |
| marketcap.company | $156.31 Million USD |
| Reuters | $156.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more